Download presentation
Presentation is loading. Please wait.
1
Volume 104, Pages 119-125 (February 2017)
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC Yi-Long Wu, Nagahiro Saijo, Sumitra Thongprasert, J. C.-H. Yang, Baohui Han, Benjamin Margono, Busayamas Chewaskulyong, Patrapim Sunpaweravong, Yuichiro Ohe, Yukito Ichinose, Jin-Ji Yang, Tony S.K. Mok, Helen Young, Vincent Haddad, Yuri Rukazenkov, Masahiro Fukuoka Lung Cancer Volume 104, Pages (February 2017) DOI: /j.lungcan Copyright © 2016 The Authors Terms and Conditions
2
Fig. 1 Patient disposition (CONSORT diagram).
Lung Cancer , DOI: ( /j.lungcan ) Copyright © 2016 The Authors Terms and Conditions
3
Fig. 2 A. PFS by original IPASS investigator-assessment (EGFR mutation-positive ITT population). B. PFS by BICR (EGFR mutation-positive ITT population). Lung Cancer , DOI: ( /j.lungcan ) Copyright © 2016 The Authors Terms and Conditions
4
Fig. 3 A. PFS by BICR (EGFR mutation-positive ITT population) − exon 19 deletion. B. PFS by BICR (EGFR mutation-positive ITT population) − L858R mutation. Lung Cancer , DOI: ( /j.lungcan ) Copyright © 2016 The Authors Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.